A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancerSagar Sardesai, Robert Wesolowski, Lai Wei et al.|Investigational New Drugs|2020Cited by 37
Stabilization of bone marrow infiltration by metastatic breast cancer with continuous doxorubicinGaurav Pahouja, Maryam B. Lustberg, Robert Wesolowski et al.|Cancer Treatment Communications|2014Cited by 19
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancerVishnu Prasath, Bhuvaneswari Ramaswamy, H. Boutrid et al.|Breast Cancer Research and Treatment|2024Cited by 12